Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Actavis offers olanzapine and line extensions

Retail The generics manufacturer has also launched carbamazepine SF oral solution and has extended its line of glaucoma products with the introduction of dorzolamide/timolol eye drops solution.

Four new products have been launched by Actavis, including olanzapine in two tablet forms, both released on day one of patent expiry.

The antipsychotic is available as film-coated and orodispersible tablets in a variety of strengths in packs of 28.

The generics manufacturer has also launched carbamazepine SF oral solution and has extended its line of glaucoma products with the introduction of dorzolamide/timolol eye drops solution.

"We are delighted that in September, Actavis has brought four generic medicines to market – two on day-one of patent expiry and two further line extensions," said Actavis director generics Michael Cann.

The products are available through major wholesalers or directly from the Actavis customer service team.  Actavis Tel: 0800 731 0370 Fax: 0800 731 0380

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD014607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel